Dogwood Therapeutics, Inc.
DWTXHealthcare|Biotechnology|US
$1.28
+0.24 (+23.08%)
DCF Value
$0.69
Cash / Share
$144984.79
Financials
Financial Snapshot
Market Cap
$48.9M
Enterprise Value
-$4948.22B
Revenue (TTM)
$100.0K
Net Income (TTM)
-$25.2M
Cash & Investments
$4948.27B
Net Cash
$4948.27B
Free Cash Flow (TTM)
-$16.5M
Operating CF (TTM)
-$16.5M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$4948.27B
Quarterly Burn
$4.1M
Monthly Burn
$1.4M
Est. Runway
~1201631.1 quarters
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $30.0K | $309.4K | $29.8M | $14.0M | $7.0M | $3.3M | $14.8M | $6.5M | $4948.27B | |
| Operating Cash Flow | -$1.2M | -$2.1M | -$3.9M | -$15.7M | -$11.5M | -$4.9M | -$8.8M | -$15.6M | -$16.5M | |
| Free Cash Flow | -$1.2M | -$2.1M | -$3.9M | -$15.7M | -$11.5M | -$4.9M | -$8.8M | -$15.6M | -$16.5M | |
| Capital Expenditure | $0.00 | $0.00 | -$5.00 | $0.00 | -$3.00 | $0.00 | $5.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $1.2M | $2.4M | $33.4M | -$97.6K | $4.5M | $1.2M | $16.7M | $7.3M | $11.3M |
R&D Spending
R&D (TTM)
$11.6M
R&D Intensity
11607.1%
R&D Growth vs Prior
-46.9%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $100.0K | |
| R&D Expense | $854.1K | $800.6K | $194.0K | $10.8M | $8.1M | $1.7M | $3.5M | $21.9M | $11.6M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | 11607.1% | |
| SG&A | $1.1M | $1.4M | $9.8M | $4.8M | $4.2M | $3.7M | $8.7M | $6.1M | $7.1M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $100.0K | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $104.8K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$4.8K | |
| R&D | $854.1K | $800.6K | $194.0K | $10.8M | $8.1M | $1.7M | $3.5M | $21.9M | $11.6M | |
| SG&A | $1.1M | $1.4M | $9.8M | $4.8M | $4.2M | $3.7M | $8.7M | $6.1M | $7.1M | |
| Operating Income | -$2.0M | -$2.2M | -$10.0M | -$15.6M | -$12.3M | -$5.4M | -$12.2M | -$28.0M | -$18.7M | |
| Interest Expense | $152.1K | $295.1K | $384.2K | $0.00 | $0.00 | $0.00 | $92.2K | $0.00 | $0.00 | |
| Pretax Income | -$2.1M | -$2.5M | -$10.3M | -$16.0M | -$12.2M | -$5.3M | -$12.4M | -$34.0M | -$27.6M | |
| Net Income | -$2.1M | -$2.5M | -$10.3M | -$16.0M | -$12.2M | -$5.3M | -$12.3M | -$34.3M | -$25.2M | |
| EPS (Diluted) | -10.93 | -12.80 | -52.50 | -47.90 | -27.66 | -7.05 | -12.52 | -4.32 | -0.89 | |
| EBITDA | -$2.0M | -$2.2M | -$10.0M | -$16.0M | -$12.2M | -$5.3M | -$12.2M | -$34.0M | -$18.5M | |
| Shares Out. (M) | 0.19 | 0.19 | 0.20 | 0.33 | 0.44 | 0.75 | 1.03 | 8.22 | 34.13 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.0K | $309.4K | $29.8M | $14.0M | $7.0M | $3.3M | $14.8M | $6.5M | $4948.27B | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $42.4K | $315.9K | $31.5M | $15.8M | $8.4M | $4.2M | $16.5M | $8.4M | $4948.27B | |
| Total Assets | $65.9K | $315.9K | $31.5M | $15.8M | $8.4M | $4.2M | $94.3M | $90.2M | $75.6M | |
| Total Current Liabilities | $1.3M | $1.6M | $1.5M | $1.3M | $1.0M | $358.5K | $3.2M | $3.1M | $2.2M | |
| Long-Term Debt | $0.00 | $3.6M | $0.00 | $0.00 | $0.00 | $0.00 | $15.4M | $0.00 | $58.9K | |
| Total Liabilities | $1.3M | $5.3M | $1.5M | $1.3M | $1.0M | $358.5K | $30.0M | $15.3M | $11.5M | |
| Stockholders' Equity | -$1.3M | -$4.9M | $29.9M | $14.5M | $7.3M | $3.8M | $64.3M | $74.9M | $64133.22B | |
| Retained Earnings | -$15.1M | -$17.6M | -$28.0M | -$43.9M | -$56.2M | -$61.5M | -$73.8M | -$108.1M | -$129.5M |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.2M | -$2.1M | -$3.9M | -$15.7M | -$11.5M | -$4.9M | -$8.8M | -$15.6M | -$16.5M | |
| Capital Expenditure | $0.00 | $0.00 | -$5.00 | $0.00 | -$3.00 | $0.00 | $5.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$1.2M | -$2.1M | -$3.9M | -$15.7M | -$11.5M | -$4.9M | -$8.8M | -$15.6M | -$16.5M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $3.8M | $0.00 | $0.00 | |
| Financing Cash Flow | $1.2M | $2.4M | $33.4M | -$97.6K | $4.5M | $1.2M | $16.7M | $7.3M | $11.3M | |
| Issuance of Stock | $0.00 | $0.00 | $31.3M | $0.00 | $4.5M | $1.2M | $1.4M | $4.3M | $11.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | -$295.2K | $0.00 | $0.00 | -$351.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $2.4M | $2.0M | $0.00 | $0.00 | $0.00 | $15.3M | $3.0M | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $7.4M | $322.9K | $582.7K | $620.0K | $476.0K | $355.6K | $1.7M | |
| Net Change in Cash | -$45.5K | $279.4K | $29.5M | -$15.8M | -$7.0M | -$3.7M | $11.5M | -$8.3M | -$5.2M |
Dilution Tracker
Shares outstanding grew 4071.1% over 5 years — significant dilution
Shares Outstanding
38M
5-Year Share Growth
+4071.1%
Stock Issuance (TTM)
$11.5M
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.19 | 0.19 | 0.20 | 0.33 | 0.44 | 0.75 | 1.03 | 8.22 | 34.13 | |
| Change vs Prior % | — | 0.0% | 2.0% | 69.1% | 32.9% | 69.6% | 36.8% | 699.8% | 315.2% | |
| Stock Issuance | $0.00 | $0.00 | $31.3M | $0.00 | $4.5M | $1.2M | $1.4M | $4.3M | $11.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | -$295.2K | $0.00 | $0.00 | -$351.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $7.4M | $322.9K | $582.7K | $620.0K | $476.0K | $355.6K | $1.7M |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | — | — | — | -4.8% | |
| Operating Margin % | — | — | — | — | — | — | — | — | -18672.6% | |
| Net Margin % | — | — | — | — | — | — | — | — | -25179.6% | |
| EBITDA Margin % | — | — | — | — | — | — | — | — | -18456.9% | |
| FCF Margin % | — | — | — | — | — | — | — | — | -16471.8% | |
| ROE % | 167.7% | 50.0% | -34.6% | -110.1% | -167.2% | -139.1% | -19.2% | -45.7% | -0.0% | |
| ROA % | -3205.6% | -783.0% | -32.9% | -101.2% | -146.3% | -127.1% | -13.1% | -38.0% | -33.3% | |
| ROIC % | 155.6% | 166.9% | -33.4% | -107.9% | -168.1% | -143.1% | -13.4% | -32.1% | -0.0% | |
| R&D / Revenue % | — | — | — | — | — | — | — | — | 11607.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -11.1% | -359.3% | -56.3% | 21.3% | 55.8% | -124.5% | -128.7% | |
| Net Income | 0.0% | -17.0% | -318.3% | -54.3% | 23.3% | 56.8% | -133.2% | -177.4% | |
| EPS (Diluted) | 0.0% | -17.1% | -310.2% | 8.8% | 42.3% | 74.5% | -77.6% | 65.5% | |
| Operating Cash Flow | 0.0% | -74.9% | -86.2% | -302.8% | 26.9% | 57.5% | -80.5% | -77.7% | |
| Free Cash Flow | 0.0% | -74.9% | -86.2% | -302.8% | 26.9% | 57.5% | -80.5% | -77.7% | |
| R&D Expense | 0.0% | -6.3% | -75.8% | 5464.4% | -25.3% | -78.6% | 104.3% | 519.3% | |
| SG&A Expense | 0.0% | 24.4% | 612.1% | -50.6% | -12.4% | -12.4% | 133.8% | -29.8% | |
| Total Assets | 0.0% | 379.1% | 9862.9% | -49.9% | -46.9% | -50.2% | 2164.1% | -4.4% | |
| Book Value / Share | 0.0% | -292.1% | 694.2% | -71.4% | -62.0% | -69.4% | 1133.9% | -85.4% | |
| Debt | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | -99.0% | |
| Diluted Shares | 0.0% | 0.0% | 2.0% | 69.1% | 32.9% | 69.6% | 36.8% | 699.8% |
Valuation
P/E (TTM)At Loss
P/S489.32
P/B0.00
10Y Low / Med / High0.04 / 1.24 / 2.94
EV/EBITDA268095.59
EV/Revenue-49482169.50
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.69
Net Current Assets / Share
$129440.92
Graham Net-Net
$144984.45
Cash / Share
$144984.79
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -38.22 | -32.64 | -3.58 | -2.67 | -0.21 | -2.04 | -0.20 | -0.96 | -1.44 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 489.32 | |
| P/B Ratio | -64.07 | -16.34 | 1.24 | 2.94 | 0.36 | 2.84 | 0.04 | 0.46 | 0.00 | |
| EV/EBITDA | -41.15 | -38.59 | -0.72 | -1.79 | 0.36 | -1.41 | -0.27 | -0.82 | 268095.59 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -49482169.50 |
Analyst Estimates & Quality
Altman Z-Score
78534.69
Safe
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $128.8M | $18.7M | $9.4M |
| Net Income | -$7.2M | -$5.9M | -$6.6M |
| EPS | $-0.88 | $-0.72 | $-0.77 |
| # Analysts (EPS) | 1 | 2 | 3 |